#GI102
LightNews LightNews
oncodaily.bsky.social
GI Innovation Dosed First Patient in Phase 1 Trial of “GI-102” Immuno-Oncology Drug

oncodaily.com/insight/211795

#Cancer #GI #INNOVATION #GI102 #Immunotherapy #OncoDaily #Oncology #Medicine #Health
GI Innovation Dosed First Patient in Phase 1 Trial of "GI-102" Immuno-Oncology Drug - OncoDaily
GI Innovation Dosed First Patient in Phase 1 Trial of "GI-102" Immuno-Oncology Drug / cancer, GI INNOVATION, GI-102, immunotherapy, Kim Seung-tae, OncoDaily,
oncodaily.com
December 27, 2024 at 4:45 PM